Benefit of EGFR Mutation Analysis from Plasma Cell-Free DNA for Treatment of Advanced Non-Small Cell Lung Cancer

Osimertinib: A New Option in Non-Small Cell Lung Cancer - Q&A with David R. Gandara, MD, and Federico Cappuzzo, MD, PhD

Alectinib and ALK-Positive Non-Small Cell Lung Cancer - Q&A with Alice T. Shaw, MD, PhD, and Ranee Mehra, MD

PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

National Comprehensive Cancer Network NSCLC Guideline Updates for 2016: Non-Small Cell Lung Cancer

Afatinib Outperforms Gefitinib in Advanced Non-Small Cell Lung Cancer

Update on Checkpoint Inhibitors in Lung Cancer

HER2 Mutations Present Unique Challenges in NSCLC

Targeted Therapies Expanding for MET Dysregulation in NSCLC

Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration

Guideline-Concordant Surgery, Adjuvant Therapy, and the Promise of Curative-Intent Lung Cancer Surgery: What Are We Up Against?

From the Editor: Looking Back on 2022